

Article title: Assessment of Financial Impact of Expanding the Scope of Drug Usage in South Korea

Journal name: International Journal of Health Policy and Management (IJHPM)

Authors' information: Su-Yeon Yu¹, Dong-Sook Kim², Hyungmin Kim^{3,4}, Junwoo Jo⁵, Hyunduck Kim³, Euna Han^{6*}

¹College of Pharmacy, Kangwon National University, Chuncheon, Republic of Korea.

²Department of Health Administration, College of Nursing and Health, Kongju National University, Kongju, Republic of Korea.

³Department of Drug Management, National Health Insurance Service, Wonju, Republic of Korea.

⁴College of Pharmacy, Seoul National University, Seoul, Republic of Korea.

⁵Department of Statistics, Kyungpook National University, Daegu, Republic of Korea.

⁶College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea.

***Correspondence to:** Euna Han; Email: eunahan@yonsei.ac.kr

Citation: Yu SY, Kim DS, Kim H, Jo J, Kim H, Han E. Assessment of financial impact of expanding the scope of drug usage in South Korea. Int J Health Policy Manag. 2025;14:8812. doi:[10.34172/ijhpm.8812](https://doi.org/10.34172/ijhpm.8812)

Supplementary file 1

Table S1: List of Ingredients in Analyzed Drugs

Abiraterone Acetate
Alectinib Hydrochloride (as Alectinib)
Atezolizumab
Atomoxetine 1
Atomoxetine 2
Bedaquiline Fumarate (as Bedaquiline)
Belimumab
Bevacizumab
Blinatumomab
Capecitabine
Celecoxib
Cetuximab
Clostridium Botulinum A Toxin
Clostridium Botulinum Toxin Type A Haemagglutinin Complex

Crizotinib
Dabrafenib Mesylate (as Dabrafenib)
Defibrotide
Denosumab 1
Denosumab 2
Dupilumab
Eculizumab
Emicizumab
Enzalutamide
Everolimus
Fulvestrant
Human-Derived Epidermal Keratinocyte
Ibrutinib Inotuzumab
Ozogamicin
Iron Hydroxide Sucrose Complex
Lenvatinib
Methylphenidate
Niraparib Tosylate (as Niraparib)
Nivolumab
Olaparib
Oxaliplatin

Paclitaxel (Albumin-Bound)

Palbociclib
Pembrolizumab
Pemetrexed 1
Pemetrexed 2
Pertuzumab
Pomalidomide Propofol
Recombinant Blood Coagulation Factor IX, Nonacog A
Recombinant Blood Coagulation Factor VIII

Regorafenib Hydrate (as Regorafenib)

Ribociclib Succinate (as Ribociclib)

Sacubitril/Valsartan

Somatropin Sorafenib

Tegoprazan

Tenofovir Disoproxil Fumarate

Tocilizumab

Tolvaptan Sd Powder (as Tolvaptan)

Trametinib Dimethyl Sulfoxide (as Trametinib)

Trastuzumab Emtansine (as Trastuzumab)

Venetoclax




Figure S1. Overview of interrupted time-series analysis.

Note. We performed the interrupted time-series analysis based on follow-up periods of 12, 24, and 36 months after indication expansion, comparing them to the pre-expansion period of 18 months. The expansion timing varies for each drug.




Figure S2. Annual Trends of total pharmaceuticals covered by National Health Insurance. (A) ingredients. (B) products.